Pharvaris (PHVS) to Release Quarterly Earnings on Wednesday

Key Points

• Pharvaris (NASDAQ:PHVS) is expected to report its Q1 2025 earnings results on August 13th, with analysts forecasting losses of ($0.87) per share.
• The company missed previous earnings expectations, reporting ($0.89) EPS in its last quarter, and analysts project $-3 EPS for both the current and next fiscal years.
• Pharvaris has a consensus rating of Buy and an average price target of $36.20, with several firms issuing positive ratings and price targets up to $32.00.

Pharvaris (NASDAQ:PHVS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Price Performance

Shares of PHVS stock traded down $0.20 during mid-day trading on Friday, hitting $20.12. 123,961 shares of the stock traded hands, compared to its average volume of 219,938. The stock has a market cap of $1.05 billion, a P/E ratio of -6.68 and a beta of -2.81. The stock's fifty day moving average is $19.21 and its two-hundred day moving average is $17.13. Pharvaris has a 52-week low of $11.51 and a 52-week high of $26.33.

Institutional Trading of Pharvaris

An institutional investor recently raised its position in Pharvaris stock. Geode Capital Management LLC increased its stake in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) by 41.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,102 shares of the company's stock after buying an additional 15,769 shares during the quarter. Geode Capital Management LLC owned about 0.10% of Pharvaris worth $952,000 as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on PHVS shares. Wedbush reaffirmed an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Cantor Fitzgerald lowered their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Finally, Guggenheim initiated coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $36.20.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.